摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

ethyl isocyanoacetate

中文名称
——
中文别名
——
英文名称
ethyl isocyanoacetate
英文别名
ethyl 2-isocyanoacetate
ethyl isocyanoacetate化学式
CAS
——
化学式
C5H9NO2
mdl
——
分子量
115.132
InChiKey
YDDNOXYCIDJIOE-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    0.1
  • 重原子数:
    8
  • 可旋转键数:
    4
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.6
  • 拓扑面积:
    38.3
  • 氢给体数:
    1
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    ethyl isocyanoacetatecopper(I) oxideammonium hydroxidesodium hypochlorite1,10-菲罗啉甲基三辛基氯化铵氯化铵 、 sodium hydroxide 作用下, 以 1,4-二氧六环甲基叔丁基醚 为溶剂, 反应 7.0h, 生成 diethyl 1-amino-1H-pyrrole-2,4-dicarboxylate
    参考文献:
    名称:
    [EN] SUBSTITUTED PYRROLO TRIAZINE CARBOXAMIDE DERIVATIVES AS PROSTAGLANDIN EP3 RECEPTOR ANTAGONISTS
    [FR] DÉRIVÉS DE PYRROLO TRIAZINE CARBOXAMIDE SUBSTITUÉS EN TANT QU'ANTAGONISTES DU RÉCEPTEUR DE LA PROSTAGLANDINE EP3
    摘要:
    这项发明涉及式(I)的取代吡咯三嗪羧酰胺衍生物,以及它们的制备方法,还有用于制备治疗和/或预防疾病的药物,特别是心血管疾病,优选为血栓性或血栓栓塞性疾病,糖尿病,以及泌尿生殖和眼科疾病。
    公开号:
    WO2021094209A1
点击查看最新优质反应信息

文献信息

  • [EN] UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'URÉE OU SEL PHARMACOLOGIQUEMENT ACCEPTABLE DE CE DERNIER
    申请人:KYORIN SEIYAKU KK
    公开号:WO2016189877A1
    公开(公告)日:2016-12-01
    The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
    本发明提供了一种尿素化合物或其药理学上可接受的盐,具有类似甲酰肽受体1(以下简称为FPRL1)的激动剂作用,含有该尿素化合物或其药理学上可接受的盐的药物组合物,以及其药用。已发现下述一般式(I)所代表的尿素衍生物或其药理学上可接受的盐具有优越的FPRL1激动剂作用。化合物(I)或其药理学上可接受的盐对于治疗、预防或抑制炎症性疾病、慢性气道疾病、癌症、败血症、过敏症状、HIV逆转录病毒感染、循环障碍、神经炎症、神经障碍、疼痛、朊病、淀粉样变性、免疫障碍等方面非常有用。
  • [EN] SUBSTITUTED BICYCLIC PYRIMIDINE-BASED COMPOUNDS AND COMPOSITIONS AND USES THEREOF<br/>[FR] COMPOSÉS BICYCLIQUES SUBSTITUÉS À BASE DE PYRIMIDINE, COMPOSITIONS ET UTILISATIONS ASSOCIÉES
    申请人:THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING / MCGILL UNIV
    公开号:WO2018137036A1
    公开(公告)日:2018-08-02
    Novel C-2-substituted bicyclic compounds of Formula I have been prepared and found to be useful as potent inhibitors of hGGPPS by inhibiting geranylgeranylation of proteins and inhibiting the biosynthesis of GGPP. The application is directed to these compounds, to compositions comprising these compounds, and to their use, in particular as medicaments for use in the treatment of cancer and other conditions which are treatable by inhibiting human geranylgeranylation pyrophosphate hGGPPS activity.
    已经制备了Formula I的新型C-2取代双环化合物,并发现它们作为hGGPPS的有效抑制剂,通过抑制蛋白质的戊二烯基酰基化和抑制GGPP的生物合成而被发现是有用的。该申请涉及这些化合物,包括这些化合物的组合物,以及它们的用途,特别是作为用于治疗癌症和其他可通过抑制人类戊二烯基酰基化焦磷酸盐hGGPPS活性的药物。
  • [EN] METHODS OF USE FOR PYRIMIDINES AS FERROPORTIN INHIBITORS<br/>[FR] MÉTHODES D'UTILISATION DE PYRIMIDINES EN TANT QU'INHIBITEURS DE LA FERROPORTINE
    申请人:GLOBAL BLOOD THERAPEUTICS INC
    公开号:WO2021222483A1
    公开(公告)日:2021-11-04
    The subject matter described herein is directed to ferroportin inhibitor compounds of Formula (I) and pharmaceutical salts thereof, methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for prophylaxis and/or treatment of diseases caused by a lack of hepcidin or iron metabolism disorders, particularly iron overload states, such as thalassemia, sickle cell disease and hemochromatosis, and also kidney injuries.
    本文描述的主题是针对化学式(I)的铁蛋白抑制剂化合物及其药用盐,制备这些化合物的方法,包含这些化合物的药物组合物,以及用于预防和/或治疗由于缺乏肝铁蛋白或铁代谢紊乱引起的疾病的方法,特别是铁超载状态,如地中海贫血、镰状细胞病和血色病,以及肾损伤。
  • Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents
    作者:Ju Liu、Fang Liu、Zhen Li、Chunyan Li、Shuang Wu、Jiwei Shen、Huan Wang、Siyuan Du、Hao Wei、Yunlei Hou、Shi Ding、Ye Chen
    DOI:10.1016/j.bioorg.2022.105629
    日期:2022.3
    Two series of novel 4-phenoxypyridine derivatives containing imidazole-4-carboxamide and 4-methyl-5-oxo-4,5-dihydro-1,2,4-triazole-3-carboxamide moieties were synthesized and evaluated for their in vitro inhibitory activities against c-Met kinase and antiproliferative activities against MKN-45, A549 and H460 cancer cell lines. The results indicated that most of the compounds showed moderate to good
    合成了两个系列的新型 4-苯氧基吡啶衍生物,含有咪唑-4-甲酰胺和 4-甲基-5-氧代-4,5-二氢-1,2,4-三唑-3-甲酰胺部分,并评估了它们的体外抑制作用对 c-Met 激酶的活性和对 MKN-45、A549 和 H460 癌细胞系的抗增殖活性。结果表明,大多数化合物显示出中等至良好的抗肿瘤活性。最有希望的化合物T14(c-Met IC 50值为 0.012 μM)对 MKN-45、A549 和 H460 细胞系显示出显着的抗增殖活性,IC 50值分别为 0.64 μM、1.92 μM 和 2.68 μM。他们初步的构效关系(SARs)研究表明,4-咪唑酰胺更优选作为连接部分,末端苯环上的吸电子基团(尤其是卤素基团)有利于提高抗肿瘤活性。
  • Two tandem multicomponent reactions for the synthesis of sequence-defined polymers
    作者:Lu Yang、Ze Zhang、Bofei Cheng、Yezi You、Decheng Wu、Chunyan Hong
    DOI:10.1007/s11426-015-5448-0
    日期:2015.11
    Multicomponent polymerizations have become powerful tools for the construction of sequence-defined polymers. Although the Passerini multicomponent reaction has been widely used in the synthesis of sequence-defined polymers, the tandem usage of the Passerini multicomponent reaction and other multicomponent reactions in one-pot for the synthesis of sequence-defined polymers has not been developed until now. In this contribution, we report the tandem usage of the Passerini three-component reaction and the three-component amine-thiol-ene conjugation reaction in one pot for the synthesis of sequence-defined polymers. The Passerini reaction between methacrylic acid, adipaldehyde, and 2-isocyanobutanoate was carried out, affording a new molecule containing two alkene units. Subsequently, an amine and a thiolactone were added to the reaction system, whereupon the three-component amine-thiol-ene conjugating reaction occurred to yield a sequence-defined polymer. This method offers more rapid access to sequence-defined polymers with high molecular diversity and complexity.
    多组分聚合已成为构建序列定义聚合物的强大工具。尽管Passerini多组分反应已广泛应用于序列定义聚合物的合成,但迄今为止,在一锅中联用Passerini多组分反应和其他多组分反应来合成序列定义聚合物尚未得到发展。在此项研究中,我们报告了在一锅中联用Passerini三组分反应和三组分胺-硫醇-烯结合反应来合成序列定义聚合物。我们进行了以甲基丙烯酸、戊醛和2-异氰基丁酸酯为反应物的Passerini反应,产物为含有两个烯键单元的新分子。随后,向反应体系中加入了一种胺和一种硫内酯,随后发生了三组分胺-硫醇-烯结合反应,产生了序列定义聚合物。这种方法提供了更快速获得高分子多样性和复杂性的序列定义聚合物的途径。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物